Evidence map›Paper›PMID 42788017›Full record

ArticleIranian journal of basic medical sciences2026

Combined cold atmospheric plasma and vemurafenib suppress MITF-P21 signaling and MMP-driven metastasis in cutaneous melanoma.

Zahra Yazdani, Mansooreh Mirzaei, Sadegh Fattahi, Farshad Sohbatzadeh, Saeid Abediankenari, Arefe Mousavi, Fatemeh Mirbabaei, Zeinab Rostami, Monireh Golpour, Alireza Rafiei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zahra YazdaniDepartment of Immunology, Molecular and Cell Biology Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mansooreh MirzaeiDepartment of Anatomy, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Sadegh FattahiNorth Research Center, Pasteur Institute of Iran, Amol, Iran.
Farshad SohbatzadehDepartment of Atomic and Molecular Physics, Faculty of Science, University of Mazandaran, Babolsar, Iran.
Saeid AbediankenariImmunogenetics Research Center, Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Arefe MousaviDepartment of Basic Sciences, Sari Agricultural Sciences and Natural Resources University, Sari, Iran.
Fatemeh MirbabaeiDepartment of Basic Sciences, Sari Agricultural Sciences and Natural Resources University, Sari, Iran.
Zeinab RostamiDepartment of Immunology, Molecular and Cell Biology Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Monireh GolpourCancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Alireza RafieiDepartment of Immunology, Molecular and Cell Biology Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study investigated the anti-tumor efficacy of combined cold atmospheric plasma (CAP) and Vemurafenib (VEM) treatment (CAP plus VEM) in cutaneous melanoma, focusing on the MITF-P21 axis and MMP-driven metastasis. Materials and Methods: The therapeutic effects of CAP and VEM were evaluated using Results: CAP and VEM significantly inhibited melanoma cell proliferation and migration, with the CAP plus VEM showing the most pronounced effect. In vitro, all treatments markedly down-regulated Conclusion: The CAP plus VEM enhances anti-tumor efficacy and suppresses metastasis-related pathways in melanoma, both

Indexed as

AnimalIn vitroIn vivoMatrix metalloproteinases- ModelsMelanomaPlasma gasesVemurafenib

Identifiers

PMID42788017
PMCPMC13602863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.